dc.contributor | Universidade de São Paulo (USP) | |
dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2014-05-27T11:28:17Z | |
dc.date.available | 2014-05-27T11:28:17Z | |
dc.date.created | 2014-05-27T11:28:17Z | |
dc.date.issued | 2013-02-01 | |
dc.identifier | Tumor Biology, v. 34, n. 1, p. 139-143, 2013. | |
dc.identifier | 1010-4283 | |
dc.identifier | 1423-0380 | |
dc.identifier | http://hdl.handle.net/11449/74458 | |
dc.identifier | 10.1007/s13277-012-0521-1 | |
dc.identifier | WOS:000313875400018 | |
dc.identifier | 2-s2.0-84872783923 | |
dc.description.abstract | The aim of this study was to investigate the expression of vascular endothelial growth factor type C (VEGF-C) in oral squamous cell carcinoma (OSCC) cell lines through norepinephrine-induced activation of beta-adrenergic receptors. Human OSCC cell lines (SCC-9 and SCC-25) expressing beta-adrenergic receptors were stimulated with different concentrations of norepinephrine (0.1, 1, and 10 μM) and 1 μM of propranolol, and analyzed after 1, 6, and 24 h. VEGF-C gene expression and VEGF-C production in the cell supernatant were evaluated by real-time PCR and by ELISA, respectively. The results showed that beta-adrenergic receptor stimulation by different concentrations of norepinephrine or blocking by propranolol did not markedly alter VEGF-C expression by SCC-9 and SCC-25 cells. VEGF-C protein levels produced by oral malignant cell lines after stimulation with different norepinephrine concentrations or blocking with propranolol was statistically similar (p > 0.05) to those of the control group (nonstimulated OSCC cell lines). Our findings suggest that stimulation of beta-adrenergic receptors by means of norepinephrine does not seem to modulate the VEGF-C expression in OSCC cell lines. These findings reinforce the need for further studies in order to understand the responsiveness of oral cancer to beta-adrenergic receptor stimulation or blockage, especially with regard to VEGF-C production. © 2012 International Society of Oncology and BioMarkers (ISOBM). | |
dc.language | eng | |
dc.relation | Tumor Biology | |
dc.relation | 1,149 | |
dc.relation | 1,149 | |
dc.rights | Acesso restrito | |
dc.source | Scopus | |
dc.subject | Adrenergic receptors | |
dc.subject | Oral cancer | |
dc.subject | VEGF | |
dc.subject | beta adrenergic receptor | |
dc.subject | noradrenalin | |
dc.subject | propranolol | |
dc.subject | vasculotropin C | |
dc.subject | cancer cell | |
dc.subject | cancer cell culture | |
dc.subject | cell line SCC 25 | |
dc.subject | cell line SCC 9 | |
dc.subject | controlled study | |
dc.subject | enzyme activation | |
dc.subject | enzyme activity | |
dc.subject | enzyme synthesis | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | in vitro study | |
dc.subject | mouth squamous cell carcinoma | |
dc.subject | priority journal | |
dc.subject | protein analysis | |
dc.subject | protein expression | |
dc.subject | protein function | |
dc.subject | Adrenergic beta-Antagonists | |
dc.subject | Carcinoma, Squamous Cell | |
dc.subject | Cell Line, Tumor | |
dc.subject | Humans | |
dc.subject | Mouth Neoplasms | |
dc.subject | Neurotransmitter Agents | |
dc.subject | Norepinephrine | |
dc.subject | Propranolol | |
dc.subject | Receptors, Adrenergic, beta | |
dc.subject | Vascular Endothelial Growth Factor C | |
dc.title | VEGF-C expression in oral cancer by neurotransmitter-induced activation of beta-adrenergic receptors | |
dc.type | Artículos de revistas | |